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INTRODUCTION

Bromethalin is N-demethylated by the hepatic mixed
function oxidase (mfo) system to its desmethylbromethalin
metabolite (Fig. 1). Desmethylbromethalin has been
demonstrated to be a 10- to 1000-fold more potent uncoupler
of oxidative phosphorylation than is bromethalin (VanLier and
Cherry 1988). The apparent lack of toxicity of bromethalin
observed in guinea pigs may be partially explained by their
relative deficiency in N-demethylase activity. Production of
desmethylbromethalin, therefore, appears to be involved in the
production of the toxic syndrome. The use of an antimetabolite which inhibits the conversion of bromethalin to its
desmethylbromethalin metabolite may represent another
potential treatment for bromethalin toxicosis.
An ideal antimetabolite of bromethalin should have the
following characteristics: a) it should be metabolized by the
same microsomal isozymes which N-demethylates bromethalin,
b) it should be low in toxicity, and c) it should be readily
available. Based upon these considerations aminophylline
(theophylline ethylenediamine) was selected as a potential
bromethalin antimetabolite. Theophylline is a 1,3-dimethylated
xanthine which is similar in structure to caffeine and
theobromine (Fig. 2). Theophylline is metabolized by two Ndemethylations and an 8-hydroxylation to form 1methylxanthine, 3-methylxanthine, and 1,3-dimethyluric acid
(Lohman and Meich 1976). Studies of the in vitro
metabolism of theophylline by human microsomes indicate
that two distinct cytochrome P-450 isozymes are involved in
these reactions (Robson et al. 1988). Theophylline is
commonly used as a bronchodilator and is readily available.
Theophylline is of moderate oral toxicity with an acute oral
LD 50 of 300 mg/kg in the dog and 700 mg/kg in the cat.

The reported LD 50 for technical grade bromethalin
ranges from 1.8 mg/kg in the cat, 4.7 mg/kg in the dog, and
13 mg/kg in rabbits, and up to >1000 mg/kg in guinea pigs
(VanLier and Ottosen 1981, VanLier and Cherry 1988).
Mitochondrial electron transport studies using purified rat
brain and liver mitochondria have been performed, and have
established that bromethalin is an effective uncoupler of
oxidative phosphorylation (VanLier and Ottosen 1981, Cherry
et al. 1982, VanLier and Cherry 1988). Mitochondrial
oxidative phosphorylation is the major mechanism for
production of ATP in the brain. Uncoupling of this reaction
in bromethalin-poisoned animals may result in a lack of
adequate ATP formation and diminished Na + - K + ion
channel pump activity. We are currently investigating
alternate mechanisms of action for bromethalin toxicosis in the
rat. Regardless of mechanism of action, cerebral edema and
elevated cerebrospinal fluid pressure (CSFP) develops.
Microscopic examination of neurologic tissues (brain and
spinal cord) from lethally dosed animals revealed diffuse
spongy degeneration of the white matter and intramyelinic
edema (VanLier and Cherry 1988, Dorman et al. 1990).
The toxic syndrome induced by bromethalin is dosedependent. Rats given high oral doses (in excess of the
LD50) of bromethalin develop an acute toxic syndrome
characterized by severe muscle tremors, hyperexcitability, and
seizures (VanLier and Cherry 1988). Death may result within
8 to 24 hours due to apparent respiratory arrest. Following
the ingestion of lower oral doses (less than an LD 50 ) the
onset of clinical signs may be delayed (e.g., 24 to 86 hours).
This second syndrome is characterized in the rat by the
development of hindlimb weakness, paralysis, prostration, and
lethargy (VanLier and Cherry 1988).

Bromethalin

Desmethylbromethalin

Figure 1. Metabolism of bromethalin.
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monitored with neurologic and physical examinations for 2
hours following dosing. The rats were then monitored at 2hour intervals until euthanasia was performed. Euthanasia
with an intraperitoneal overdose of pentobarbital was
performed if an animal displayed severe or persistent seizures
(≥15 minutes of persistent seizure activity) or if paralysis was
present for 24 or more hours.
Twenty adult (50-54 days, 200-225 gram), male, colonybred Sprague-Daley rats were evenly assigned to either a
bromethalin and saline or a bromethalin and aminophylline
treatment group. Rats were housed in standard plastic rodent
cages (2 rats per cage), and were fed commercial rodent chow
and water ad libitum. Food was withheld for 4 hours prior
to bromethalin administration. Hexane-dissolved bromethalin
(analytical grade bromethalin, donated by Lilly Research
Laboratory, Greenfield, IN) was given (4.5 mg/kg) to all rats
by gavage (total volume <0.5 ml). Aminophylline (ElkinsSinn, Inc., Cherry Hills NJ) was given (15 mg/kg, IM, every
6 hours). An equivalent volume of saline was given to all
bromethalin-no treatment (control) rats. Clinical signs, time
to onset of signs, and survival time were recorded. Data
concerning mean survival time were analyzed with a one-way
ANOVA Significance was determined for all results at P ≤
0.05.

The purpose of this report is to further define the toxicity
of bromethalin-based rodenticides in nontarget species by
presenting the clinical signs associated with spontaneous
bromethalin rodenticide ingestion. Furthermore, we also
examined the efficacy of aminophylline administration in the
treatment of lethal bromethalin toxicosis in the rat.

Figure 2. Structure of theophylline.

MATERIALS AND METHODS
A. Retrospective Epidemiologic Study
Epidemiologic and clinical information was compiled from
the Illinois Animal Poison Information Center (IAPIC) case
record database. The IAPIC is located at the University of
Illinois and receives calls from throughout the United States
and Canada. The IAPIC protocol collects the following
information whenever possible: the animal’s age, sex, breed,
species, number at risk, number exposed, the number of
animals affected, the amount of product involved, source of
the animal's exposure, place where the exposure occurred, and
the level of assurance of exposure. A clinical history is also
obtained whenever possible and includes clinical signs and
their severity, clinical chemistry alterations, pathological
findings, and the animal's response to therapy. The clinical
syndrome is also characterized by the time between the
exposure and the onset of clinical signs. The duration of the
clinical syndrome is recorded.
On the basis of clinical, temporal, and exposure histories,
IAPIC veterinarians categorize each call into one of several
subcategories including: "toxicosis," suspected toxicosis,"
"doubtful toxicosis," "exposure," or "other situation" (syndrome
due to a nontoxicologic cause). The IAPIC veterinarians will
base these decisions on expected clinical signs from available
literature, on temporal and dosage considerations, and
previous experience with the agent in question. A case is
defined as an "exposure" if clinical signs are not present at the
time of the initial call. Clinical illness believed to be due to
etiologies other than a known or suspected toxicant (e.g.,
infection, foreign body) is assessed as "other situation." If the
animal has clinical signs at the time of the call, or if the
animal subsequently develops clinical signs, a "toxicosis,"
"suspected toxicosis," or "doubtful toxicosis" assessment is
used. For a case to be assessed as a "toxicosis" all temporal,
clinical, and exposure data must be consistent with the
expected syndrome. When the syndrome described is
characteristic for a given agent but some data cannot be
obtained, the case generally is assessed as a "suspected
toxicosis." Assessment as a "toxicosis" or "suspected toxicosis"
generally is unconfirmed by analytical methodologies.

RESULTS
A. Epidemiologic Study
Of the 156 cases involving accidental bromethalin
exposure received by the Illinois Animal Poison Information
Center (IAPIC) between January 1, 1989, and December 31,
1989, 6 (3.8%) were classified as "toxicosis," 18 (11.5%) as
"suspected toxicosis," 17 (10.9%) as "doubtful toxicosis," and
112 (71.8%) as "exposure." There were 145 dogs, 41 cats, 6
pheasants, 2 goats, 1 horse, and 1 hamster reported to have
ingested a bromethalin-based rodenticide during this time
period. An estimate of amount was unavailable in 33% of all
calls assessed as "exposure." An ingestion of an amount of
bromethalin believed to be consistent with a toxicosis occurred
in 21% of all calls assessed as "exposure." The IAPIC was
contacted within less than 2 hours of ingestion in 63% of all
calls assessed as "exposure." The time duration between time
of call and ingestion was unknown for only 6% of all calls
assessed as "exposure." No age or breed predispositions were
noted for bromethalin-poisoned animals. Most bromethalin
ingestions (90%) were considered accidental and 71%
occurred in the home. During the same time period (January
1, 1989, to December 31, 1989) the IAPIC received 26,744
calls involving animals exposed to all products.
Clinical signs associated with bromethalin poisoning in 15
dogs and 13 cats were (in decreasing order): depression
(61%), ataxia (38%), tremors (32%), paralysis (18%),
vomiting (18%), seizures (15%), salivation (15%), and death
(11%). Less frequently reported clinical signs included
anorexia, diarrhea, vocalization, hyperesthesia, dyspnea,
nystagmus, and coma.
B. Aminophylline Treatment Study
One rat in the group given bromethalin and saline died
during dosing due to apparent pulmonary aspiration of
hexane. Clinical signs observed in rats included tremors,
seizures, hyperactivity, ataxia, hindlimb paralysis, anorexia,
prostration, and death. Clinical signs of bromethalin toxicosis
developed within 1 to 3 hours postdosing. Deaths occurred
in untreated rats within 2.5 to 7.5 hours of ingestion. The

B. Aminophylline Treatment Study
The experimental protocol was reviewed and accepted for
animal use and welfare by the Laboratory Animal Use
Committee of the University of Illinois. Rats were serially
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mean survival time observed in untreated rats was 4.7 hours
(n=9). Deaths occurred in aminophylline-treated rats within
1.5 to 25 hours of ingestion. The mean survival time
observed in aminophylline treated rats was 8.0 hours (n=10).
No statistically significant difference between mean survival
times was noted (P < 0.05).

uncoupler of oxidative phosphorylation, and may contribute
significantly to the toxicity of bromethalin. Further, the
relative lack of toxicity observed in a species (guinea pigs),
which is deficient in its ability to form desmethylbromethalin,
strongly suggested a role for the microsomal activation of
bromethalin. The use of a therapeutic agent which might
limit
the
N-demethylation
of
bromethalin
to
desmethylbromethalin appeared rational based upon available
toxicologic data.
Aminophylline (theophylline ethylenediamine) was selected
for its potential as a bromethalin antimetabolite, since it is Ndemethylated by cytochrome P450, relatively low in toxicity,
and readily available to veterinarians. Aminophylline
administration to rats given a uniformly lethal dose of
bromethalin was not, however, effective in prolonging rat
survival. Bromethalin administration did produce the
previously described toxic syndrome in all rats regardless of
treatment. Although aminophylline administration was not
associated with a statistically significant increase in survival
time, its administration was associated with almost a doubling
of mean survival time. Whether aminophylline administration
would be effective in modifying the more commonly observed
delayed syndrome characterized by hindlimb paralysis and
central nervous system depression associated with the ingestion
of smaller bromethalin doses (<LD 50 ) is not known. Further
studies with aminophylline or other similar drugs using lower
bromethalin doses may identify a suitable treatment for this
bromethalin-induced toxic syndrome. Based upon our current
knowledge of bromethalin metabolism and toxicity, the use of
antimetabolite agents like aminophylline may hold promise as
a treatment in the future.

DISCUSSION
Bromethalin-based rodenticides, as other modern
rodenticides, may constitute a significant hazard if improperly
used and are ingested by nontarget species. Bromethalinbased rodenticides were the sixth most commonly ingested
rodenticide by animals as reported to the IAPIC in 1987
(Trammel et al. 1989). During 1987, rodenticides with the
greatest IAPIC call volume included brodifacoum (4061 calls),
warfarin (488 calls), cholecalciferol (362 calls), bromadiolone
(225 calls), diphacinone (165 calls), and bromethalin (148
calls). Although infrequently associated with toxicosis, the
majority of bromethalin related calls to the IAPIC during
1989 occurred before clinical signs developed ("exposures").
This finding was not unexpected due to the delay (days) in
onset of the development of toxicosis. Of these calls assessed
as "exposure," over 20% involved animals which ingested an
amount of bromethalin believed to potentially cause toxicosis.
The high percentage of calls (61%) in which exposure had
occurred less than 2 hours before contacting the IAPIC
indicates a high potential for early therapeutic intervention.
As with other rodenticides, bromethalin ingestion by animals
most commonly involved dogs, occurred in the home
environment, and was considered accidental. Therefore,
efforts to instruct consumers and pest control applicators in
the safe use of this rodenticide in the home (e.g., the use of
tamper-proof bait stations) may greatly reduce inadvertent
animal exposure.
Clinical signs associated with bromethalin poisoning in
dogs and cats reported to the IAPIC in this retrospective
study included depression, ataxia, tremors, paralysis, vomiting,
seizures, salivation, and death. Less frequently reported
clinical signs included anorexia, diarrhea, vocalization,
hyperesthesia, dyspnea, nystagmus, and coma. Reported
clinical signs of bromethalin toxicosis were similar to those
seen in a suspected case of bromethalin toxicosis in a cat and
experimental studies in dogs (Martin and Johnson 1989,
Dorman et al. 1990).
Currently, treatment of bromethalin toxicosis in animals
is primarily directed towards reducing the gastrointestinal
absorption of bromethalin and controlling cerebral edema
(Carson 1989). Treatment with mannitol and dexamethasone
has been reported to reverse the development of increased
cerebral spinal fluid pressure (CSFP) in rats which were
sublethally dosed with bromethalin (VanLier and Cherry
1988). The efficacy of dexamethasone and mannitol
treatment has been studied in lethally dosed dogs (Dorman et
al. 1990b). There was no increase in survival in dogs given
this treatment. Repeated oral administration of superactivated
charcoal/sorbitol (SAC/sorbitol) was associated with a delay in
the development of clinical signs and increased survival time
when monitored for 8 days. Therefore, activated charcoal
administration appears to be a partially effective treatment in
lethally-dosed dogs (Dorman et al. 1990b).
Our limited success with treatments designed to minimize
exposure and reduce cerebral edema stimulated a search for
alternative treatment modalities. Previous studies have
indicated that desmethylbromethalin is a more potent
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